AspID


REAL-TIME PCR multiplex CE IVD test designed to detect genomic DNA of clinically relevant Aspergillus species.

AspID makes it possible to discriminate infections with Aspergillus terreus, a fungus intrinsically resistant to amphotericin B.

Aspergillus-specific qPCR assays have been proposed as alternatives to conventional diagnostic procedures for invasive aspergillosis, where early diagnosis and timely therapeutic treatment are crucial for patient survival.

The kit is validated on DNA extracted from:

  • serum
  • bronchoalveolar lavage (BAL)
  • fungal cultures.

The kit is compatible with the most common DNA extraction and Real-Time PCR tools.

  • Sensitivity <1 genome of Aspergillus spp.
  • Detection in a range of 6 orders of magnitude (target number <1 to 10^6)
  • Result in <1.5h from DNA extraction
validato su DNA estratto da siero, lavaggio bronco alveolare (BAL) e colture fungine. Il kit è compatibile coi più comuni strumenti di estrazione del DNA e Real-Time PCR

Invasive pulmonary aspergillosis, a life-saving diagnosis.

Click on questions to get answers

Quantitative Real Time PCR (qPCR) has become the most widely used molecular technology for diagnostic applications designed to detect and quantify pathogens. Aspergillus-specific qPCR tests have been proposed as an alternative to conventional diagnostic procedures for Invasive Aspergillosis, where early diagnosis and treatment are critical

AspID is a multiplex qPCR test using the most widely used qPCR chemistry, based on the detection of light emitted by hydrolysis probes and detected through different fluorescent channels. The kit is designed to detect genomic DNA of clinically relevant Aspergillus species, with simultaneous identification of Aspergillus terreus, which provides clinically useful information due to the latter’s intrinsic resistance to Amphotericin B.

The simultaneous identification of Aspergillus terreus provides clinically useful information due to the fungus’ intrinsic resistance to Amphotericin B (an antifungal produced by Streptomyces nodosus and commonly used to treat deep-seated and systemic mycoses).

The kit is validated to detect DNA present in direct samples: BAL, serum and plasma.

Thus, it avoids culture methods by reducing the time to diagnose Invasive Aspergillosis and increasing patient survival.

AspID is an ‘open’ kit in that it can be used on the most common instruments found in laboratories. Here are just a few of them.

 

EXTRACTION: Qiagen EZ1, QiaSymphony, Qiagen QIAamp spin column, Molysis from Molzym, Roche MagnaPure, Qiagen QIACube.

AMPLIFICATION: BioRad CFX96, Illumna Eco, PCR MAX Eco, Roche LC480 (II), BMS MIC, ABI 7500 Fast, Qiagen RotorGene

AspID enables a diagnosis in a short time, allowing the clinician to initiate specific therapy. The correct use of AspID involves evaluating and interpreting the result in relation to the patient’s clinical context.

Aspergillus is inherently present in the environment and spores are airborne, so there is the possibility of environmental contamination during test preparation. Furthermore, Aspergillus can colonise the airways without developing pathology. For this reason, the AspID result must always be assessed in relation to the host factors and clinical signs present.

The use of AspID in combination with other tests for the identification of Invasive Pulmonary Aspergillosis, such as AspLFD, an immunochromatographic test (Lateral Flow Device), allows for better patient assessment and a rapid and more accurate diagnosis.

The Journal of Fungi, published the paper ‘Evaluation of the new AspID polymerase chain reaction assay
for detection of Aspergillus species: A pilot study’.

The authors are: Juergen Prattes, Martin Hoenig, Stefanie E.-M. Zinke, Sven Heldt,Susanne Eigl, Gemma L. Johnson, Stephen Bustin, Evelyn Stelzl, Harald H. Kessler

A summary of which is given below:

The newly developed AspID PCR assay for detection of Aspergillus spp. was evaluated with an interlaboratory quality control programme panel and human bronchoalveolar lavage fluid (BALF) samples. With the quality control programme, 8 out of 9 panel members were correctly identified. With the clinical study, 36 BALF samples that had been obtained from 18 patients with invasive pulmonary aspergillosis (IPA) and 18 without IPA were investigated. Sensitivity, specificity, positive and negative likelihood ratio for the AspID assay were 94.1% (95% CI 73.3-99.9), 76.5% (95% CI 50.1-93.2), 4 (95% CI 1.7-9.5) and 0.1 (95% CI 0.01-0.5) respectively.

AspID, as well as AspLFD, can be purchased by direct negotiation on MEPA, by submitting an application to the administration office of your facility. The kit, in fact, having unique performances on the market is accompanied by a declaration of uniqueness. LionDx is at your disposal to formulate the best offer and support you in the application and purchase process.